secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0000950142-24-002817
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.02
LLM model:  deepseek-v4-flash:cloud@v2

TScan converts $15M loan principal into 3.13M shares at $4.785
--------------------------------------------------------------

- K2 HealthVentures converted $15M of convertible term loan into 3,134,796 voting common shares at $4.785/share.
- Shares issued November 20, 2024 under Section 3(a)(9) exemption; no registration statement required.
- Conversion reduces debt but dilutes existing stockholders by approximately 5.5% based on shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095014224002817/0000950142-24-002817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095014224002817/eh240560212_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-24-002817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer